Compartmentalized Biologic Assays for High-Throughput Functional Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for screening bispecific and multispecific biologics are inefficient and biased, lacking robust platforms for high-throughput screening of functionally active molecules.
Innovation Solution
Utilizing microfluidics technology with compartmentalized nano-volumes, such as droplets or microchambers, to conduct assays that allow for the expression and secretion of bispecific or multispecific biologics within nano-volumes, incorporating engineered cells that produce reporter signals upon interaction, enabling efficient screening at the single-cell level.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional multi-step screening approaches are used to screen bispecific and multispecific biologics, then individual moieties can be co-expressed and assembled in cells, but the screening process becomes inefficient and biased with low throughput
Solution Approach 1:
The patent divides the screening process into compartmentalized nano-volumes (droplets or microchambers), where each compartment independently contains and processes individual cells expressing bispecific biologics. This segmentation enables parallel processing of thousands of samples simultaneously, dramatically increasing throughput while maintaining assay simplicity through standardized compartment designs
Solution Approach 2:
The patent introduces engineered target cells expressing reporter genes as intermediaries in the screening process. These reporter cells mediate the detection of biologic activity by producing measurable signals (fluorescence, luminescence) when bound by functional bispecific biologics, enabling high-throughput automated detection without complex manual analysis
2Productivity
If large sample volumes are used in conventional screening, then sufficient material is available for multi-step assays, but the requirement for large volumes limits screening depth and efficiency
Solution Approach 1:
The patent fundamentally changes the volume parameter of the assay system by transitioning from conventional well-plate formats (milliliter scale) to compartmentalized nano-volumes (nanoliter to picoliter scale). This parameter change enables screening of large numbers of samples with minimal sample volumes, increasing screening depth and efficiency while reducing reagent consumption
3Measurement precision
If rational or random pairing of functional moieties is used, then bisspecific biologics can be assembled, but biased selection occurs and functional activity screening becomes inefficient
Solution Approach 1:
The patent employs self-service mechanisms where each cell autonomously expresses and assembles its encoded biologic variant, and each compartment autonomously performs the binding assay with reporter cells. This eliminates researcher bias in selection and assembly processes, providing unbiased functional screening. The system self-detects functional activity through automated reporter signal measurement, ensuring objective assessment of biologic variants
Data Source
AI summary
A method for performing assays in compartmentalized nano-volumes to screen for functional bispecific or multispecific biologics, including: obtaining a plurality of at least two distinct types of cells, wherein a first-type of cells are engineered to express a single genetic-variant per cell of a bispecific or multispecific biologic in a secreted form, and wherein a second-type of cells are selected or engineered to produce a positive reporter molecule signal that is triggered by a functional variant of the bispecific or multispecific biologic expressed from the single genetic-variant by the first-type cell, wherein the bispecific or multispecific biologic has target-binding moieties that bind to two different target molecules on the same cell or to two different epitopes of the same target molecule that leads to clustering, endocytosis (internalizing) and/or degradation of the bispecific or multispecific biologic and/or the target molecule(s); co-encapsulating into each of a plurality of compartmentalized nano-volumes only one cell of the first-type cell and one or more cell(s) of the second-type cell; incubating the nano-volumes over a period of time sufficient to allow the expression and secretion of the bispecific or multispecific biologic, clustering, endocytosis (internalizing) and/or degradation of the bispecific or multispecific biologic and/or target molecule(s) and expression of the positive reporter molecule signal inside the nano-volumes; collecting data representing a positive reporter molecule signal triggered by the secreted bispecific or multispecific biologics inside the nano-volumes, recovering the first type of cells from the nano-volumes that exhibit a positive reporter molecule signal, and extracting from the recovered first type of cells genetic information representing respective functional variants of the bispecific or multispecific biologics.